ClinChoice, a Global Clinical CRO, Raises $150 Million from China Investors
publication date: Jul 5, 2022
ClinChoice, a US-China-EU clinical CMO, closed a $150 million Series E round financing from China investors. Formerly known as Fountain Medical Development, the company began life in Tianjin, China and added facilities in the US. ClinChoice CEO Ling Zhen told Endpoint News the company will use the new capital to expand in Europe and Southeast Asia, possibly via M&A, while adding remote monitoring and data analytic services. The round was led by Legend Capital and co-invested by Taikang Life Insurance, Sherpa Healthcare Partners and existing shareholders Lilly Asia Ventures and Apricot Capital. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.